Inrebic (fedratinib) / BMS 
Welcome,         Profile    Billing    Logout  
 26 Diseases   13 Trials   13 Trials   886 News 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inrebic (fedratinib) / BMS
FREEDOM, NCT03755518: A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Completed
3
38
Canada, US
FEDRATINIB
Celgene, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
11/21
11/23
FREEDOM2, NCT03952039 / 2018-003411-21: An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Active, not recruiting
3
202
Europe, RoW
FEDRATINIB, Best Available Therapy (BAT)
Celgene, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis
12/22
06/25
2021-003650-23: Study to evaluate the efficacy and safety of fedratinib in combination with CC-486 in patients suffering from myelofibrosis in acute phase. Studie zur Beurteilung der Wirksamkeit und Sicherheit von Fedratinib in Kombination mit CC-486 bei Patient*innen, die an einer Myelofibrose in beschleunigter Phase leiden.

Not yet recruiting
2
44
Europe
CC-486 tablets, Capsule, hard, Film-coated tablet, Inrebic® 100 mg Hartkapseln
Martin-Luther-Universität Halle-Wittenberg, Bristol-Myers Squibb
Myeloproliferative neoplasm in accelerated phase (MPN-AP) Myeloproliferative Neoplasie in akzelerierter Phase (MPN-AP), Myeloproliferative neoplasm in accelerated phase (MPN-AP) Myeloproliferative Neoplasie in beschleunigter Phase (MPN-AP), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
LIMBER-213, NCT04821791: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy.

Recruiting
2
60
US
itacitinib, INCB039110
Incyte Corporation
Myelofibrosis, Polycythemia Vera, Thrombocythemia
02/23
02/23
2020-003123-42: A study evaluating safety, tolerability and efficacy of Itacitinib in participants with primary or secondary Myelofibrosis

Not yet recruiting
2
73
Europe
Itacitinib, INCB039110, Tablet
Incyte Corporation, INCYTE CORPORATION, Incyte Corporation
Primary Myelofibrosis or Secondary Myelofibrosis, Primary Myelofibrosis or Secondary Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
NCT04629508: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Completed
2
4
Europe, US
itacitinib, INCB039110
Incyte Corporation
Myelofibrosis, Polycythemia Vera, Thrombocythemia
08/23
08/23
NCT04370301: Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Recruiting
2
20
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Asta B 518, B-518, WR-138719, JAK Inhibitor, JAK inhibitors, Janus Kinase Inhibitor, Ruxolitinib, Fedratinib, Fludarabine, Fluradosa, Recombinant Granulocyte Colony-Stimulating Factor, Recombinant Colony-Stimulating Factor 3, rhG-CSF, 143011-72-7, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Mycophenolate Mofetil, Cellcept, MMF, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, peripheral stem cell support, Peripheral Stem Cell Transplant, peripheral stem cell transplantation, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, FK-506, Tacforius, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation, Total-Body Irradiation Prior to Stem Cell Transplant, SCT_TBI, Computed Tomography, CAT Scan, Computed Axial Tomography, CT SCAN, Magnetic Resonance Imaging, MR Imaging, MRI, Bone Marrow Biopsy, Biopsy of Bone Marrow, Bone Marrow Aspiration, Biospecimen Collection, Biological Sample Collection, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
Fred Hutchinson Cancer Center
Primary Myelofibrosis, Secondary Myelofibrosis
08/26
08/29
NCT04282187: Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Recruiting
2
25
US
Decitabine, 127716, 2''-Deoxy-5-azacytidine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Ruxolitinib, 941678-49-5, INCB-18424, Jakafi, Oral JAK Inhibitor INCB18424, Fedratinib, 936091-26-8, SAR302503, TG101348, Questionnaire Administration, Pacritinib, 937272-79-2, Oral JAK2 Inhibitor SB1518, SB 1518, SB-1518, SB1518
University of Washington
Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
11/26
11/26
MCC-20963, NCT05177211: Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

Active, not recruiting
2
25
US
Fedratinib Pill, Inrebic
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia, MDS
04/25
04/26
NCT05393674: Fedratinib in Combination with Nivolumab

Active, not recruiting
2
30
Europe
Fedratinib Oral Capsule [Inrebic], Nivolumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Prof. F. Heidel, MH Hannover, Celgene International II S.á.r.l.
Primary Myelofibrosis, Secondary Myelofibrosis
12/25
06/26
NCT04446650: A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Active, not recruiting
1/2
31
Japan
Fedratinib
Celgene
Primary Myelofibrosis
10/23
10/25
NCT05127174: Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Active, not recruiting
1/2
12
US
Fedratinib Pill, Inrebic
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Myeloproliferative Neoplasm
08/25
08/25
CA011-023, NCT04817007 / 2020-002071-35: A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Active, not recruiting
1/2
216
Europe, US, RoW
BMS-986158, Ruxolitinib, Jakafi®, Fedratinib
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Myelofibrosis
05/26
05/26
NCT03983161: A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

Completed
1
39
US
Fedratinib
Celgene, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Healthy Volunteers, Hepatic Impairment
01/23
01/23
NCT04955938: A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Withdrawn
1
50
US
Ivosidenib, Tibsovo, Enasidenib, IDHIFA, Fedratinib, INREBIC
University of Chicago
IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation, Blood Cancer, Myeloproliferative Neoplasm
06/23
06/23
NCT05524857: Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Terminated
1
2
US
Fedratinib Oral Capsule 300 mg, Inrebic, Decitabine 20 mg/m2, Dacogen, Fedratinib Oral Capsule 400 mg
Joseph Jurcic, Bristol-Myers Squibb
Myeloproliferative Neoplasm
04/24
04/24
NCT03723148: Individual Patient Compassionate Use of Fedratinib

Available
N/A
US
Oral Fedratinib, FEDR
Celgene, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Myelofibrosis
 
 
REALFed, NCT05883904: Real World Evidence of Fedratinib Effectiveness in MF

Recruiting
N/A
93
Europe
Fedratinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
01/26
01/26
NCT06073847: A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Recruiting
N/A
137
RoW
Fedratinib
Bristol-Myers Squibb
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
12/27
12/27
NCT05665192: A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Recruiting
N/A
50
Europe
Bristol-Myers Squibb
Myelofibrosis
06/24
12/25

Download Options